Non-clinical drug safety evaluation (DSA) refers to the testing conducted under laboratory conditions using experimental systems to assess the safety of drugs. Drug safety evaluation is an important factor related to the success or failure of drug research and development, and it is also one of the necessary procedures and steps for new drug applications to IND and entry into clinical trials, as well as for NDA applications. However, using humans themselves as subjects to study the occurrence mechanisms and treatment processes of diseases is subject to many ethical and moral limitations, as well as in terms of time and space. Therefore, DSA usually uses experimental animals as models for research. Common types of experimental animals include rodents, dogs, pigs, non-human primates, etc. Among them, non-human primates have the strongest homology with humans and are closer to humans in many biological characteristics such as genetics, behavior, cognition, physiology, biochemistry, and anatomical structure. They are ideal experimental animals for studying the disease mechanisms of many human diseases and their therapeutic drugs, thus playing an irreplaceable and important role in drug DSA. For this reason, based on research into the market, Frost & Sullivan (Frost & Sullivan) has released an independent research report titled 'Research Report on the Outsourcing Service Market for Non-clinical Pharmaceutical R&D in China'.
